Skip to content
10-Q

Quarterly Report

Lomond Therapeutics Holdings, Inc.

0001213900-26-057605

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 14, 2026 32.2M sh
Shares Diluted Q1 2026 · Mar 31, 2026 32.2M sh
Shares Diluted Q1 2026 · Mar 31, 2025 29.28M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$4.54M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$704.95K
Cash And Equivalents Q1 2026 · Mar 31, 2026 $10.94M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $13.2M
Stockholders Equity Q1 2026 · Mar 31, 2026 $18.01M
Stockholders Equity Q1 2026 · Dec 31, 2025 $21.31M
Stockholders Equity Q1 2026 · Mar 31, 2025 $36.6M
Stockholders Equity Q1 2026 · Dec 31, 2024 $23.76M
Current Liabilities Q1 2026 · Mar 31, 2026 $9.1M
Current Liabilities Q1 2026 · Dec 31, 2025 $9.51M
Total Liabilities Q1 2026 · Mar 31, 2026 $9.1M
Total Liabilities Q1 2026 · Dec 31, 2025 $9.51M
Current Assets Q1 2026 · Mar 31, 2026 $14.13M
Current Assets Q1 2026 · Dec 31, 2025 $27.27M
Total Assets Q1 2026 · Mar 31, 2026 $27.11M
Total Assets Q1 2026 · Dec 31, 2025 $30.82M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.16
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.21
Eps Basic Q1 2026 · Mar 31, 2026 −$0.16
Eps Basic Q1 2026 · Mar 31, 2025 −$0.21
Sga Expense Q1 2026 · Mar 31, 2026 $1.05M
Sga Expense Q1 2026 · Mar 31, 2025 $1.36M
Rd Expense Q1 2026 · Mar 31, 2026 $3.62M
Rd Expense Q1 2026 · Mar 31, 2025 $5.16M
Net Income Q1 2026 · Mar 31, 2026 −$5.26M
Net Income Q1 2026 · Mar 31, 2025 −$6.2M
Operating Income Q1 2026 · Mar 31, 2026 −$4.67M
Operating Income Q1 2026 · Mar 31, 2025 −$6.52M
Short Term Investments Q1 2026 · Dec 31, 2025 $11.24M